This is a preview of subscription content, log in via an institution to check access.
Abbreviations
- COPP:
-
cyclophosphamide/Oncovin (vincristine)/procarbazine/prednisone
- ABVD:
-
Adriamycin/bleomycin/vinblastine/dacarbazine
References
Diehl V, Pfreundschuh M, Löffler M, Rühl U, Hiller E, Gerhartz W, Wilmanns H, Kirchner H, Schoppe W, Petsch S, Bartels H, Pflüger KH, Teichmann J, Fuchs R, Kühn G, Oertel W, Mertelsmann R, Hecht T, Schalk KP, Worst P, Wilhelmy M, Gassmann W, Loos U, Hinterberger R, Theml H, Wagner T, Samandari S, Schäfgen W, Preiss J, Schmitz G, Mende W, Mödder B, Schick (1989a) Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group. Med Oncol Tumor Pharmacol 6:155–162
Diehl V, Pfreundschuh M, Löffler M, Rühl U, Hiller E, Gerhartz H, Kirchner H (1989b) Combined modality therapy for stages I–IIIA massive mediastinal Hodgkin's disease (MMHD): a randomized trial of two double cycles of COPP+ABVD pluse extended-field (EF) radiotherapy 40 Gy versus 20 Gy (Bulky Disease 40 Gy). Am Soc Clin Oncol 8:253
Löffler M, Pfreundschuh M, Hasenclever D, Hiller E, Gerhartz H, Wilmann W, Rohloff R, Rühl U, Kühn G, Fuchs R, Kirchner H, Teichmann J, Schoppe W, Petsch S, Wilhelmy W, Worst P, Pflüger KH, Hecht T, Bartels H, Gassmann W, Krüger G, Schmitz G, Oertel W, Diehl V (chairman) (1988) Prognostic risk factors in advanced Hodgkin's lymphoma. Blut 56:273–281
Pfreundschuh M, Diehl V (1989) Therapie rezidivierender Hodgkin Lymphome. II. Der Stellenwert der Knochenmarktransplantation. Dtsch Med Wochenschr 114:916–921
Pfreundschuh M, Schoppe W, Fuchs R, Pflüger KH, Löffler M, Diehl V (1987) Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkins' lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group. Cancer Treat Rep 71:1203–1207
Pfreundschuh M, Löffler M, Rühl U, Hiller E, Gerhartz H, Wilmanns W, Kirchner H, Schoppe W, Petsch S, Bartels H, Pflüger KH, Teichmann J, Fuchs R, Kühn G, Oertel W, Mertelsmann R, Dölken G, Schalk KP, Worst P, Wilhelmy M, Gassmann W, Loos U, Hinterberger R, Theml H, Wagner T, Samandari S, Schäfgen W, Preiss J, Schmitz N, Mende W, Mödder B, Schick HD, Diehl V (1988) Therapy of Hodgkin's lymphomas. Results of the German Hodgkin Study Group. Onkologie 11:48–52
Pfreundschuh M, Berenbeck C, Schroeder J, Da Costa L, Jung W, Schmits R, Tschiersch A, Diehl V, Gause A (1989) Clinical significance of soluble Hodgkin-related antigen in the sera of patients with Hodgkin's lymphoma. Proc Am Soc Clin Oncol 8:273
Somers R, Henry-Amar M, Carde P, Najman A, on behalf of the EORTC Lymphoma Cooperative Group and the Group Pierre et Marie Curie (1988) MOPP vs alternating 2 MOPP/2 ABVD in advanced Hodgkin's disease (HD). Proc Am Soc Clin Oncol 7:236
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Diehl, V., Pfreundschuh, M., Löffler, M. et al. Cooperative trials of Hodgkin's lymphoma in the Federal Republic of Germany. J Cancer Res Clin Oncol 116, 106–108 (1990). https://doi.org/10.1007/BF01612650
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01612650